Furoscix FDA Approval History
Last updated by Judith Stewart, BPharm on Nov 1, 2022.
FDA Approved: Yes (First approved October 7, 2022)
Brand name: Furoscix
Generic name: furosemide
Dosage form: Injection
Company: scPharmaceuticals, Inc.
Treatment for: Heart Failure
Furoscix (furosemide) is a loop diuretic indicated for the at-home treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure.
- Furoscix is a subcutaneous formulation of the approved diuretic furosemide delivered via a wearable, pre-programmed, single-use, On-Body Infusor.
- Furoscix is administered by subcutaneous infusion over a period of five hours. The On-Body Infusor delivers an 80 mg dose at home, providing intravenous equivalent diuresis that would normally require hospital admission.
- Warnings and precautions associated with Furoscix include fluid, electrolyte, and metabolic abnormalities; worsening renal function; ototoxicity; and acute urinary retention.
- Common adverse reactions observed during treatment with the Furoscix Infusor were administration site and skin reactions: erythema, bruising, edema and infusion site pain.
Development timeline for Furoscix
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
